AKR1B10 and breast cancer: To address clinical relevance of these findings, we used a FAO 88-gene signature (FAO88; see Methods section) and demonstrated that AKR1B10 expression positively correlated with a high FAO88 score in triple negative (TN) and ER− breast cancer, but not in ER+ breast cancers (Fig. 4c) both in the TCGA dataset and in the dataset of Hatzis et al. containing 508 breast cancer patients treated with neoadjuvant chemotherapy24.